Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Refractory/Relapse Neuroblastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma 1Lung Neoplasms 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 91Carboplatin 79Specimen Handling 76Magnetic Resonance Spectroscopy 64Pemetrexed 60Cisplatin 49durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32Radiotherapy 30Radiosurgery 30osimertinib 29Blood Specimen Collection 27Biopsy 26Gemcitabine 24Docetaxel 24Immunoglobulin G 23Standard of Care 22Disulfides 22Etoposide 21Drug Therapy 21Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Biological Products × 1 year × Clear all
NCT04908111 2026-04-06

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Cancer Research UK

Phase 1/2 Suspended
15 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡